MoTarek

Hematology Resident, Bioinformatician and Synthetic Biology Enthusiast

[MoTarek @MoTarekM]

That's when I feel my life has meaning @AcademicChatter

[The Nobel Prize @NobelPrize]

"When a patient says their life was saved by the cancer therapy we developed, that's when I feel my life has meaning."

Tasuku Honjo shared the 2018 Medicine Prize with James Allison for their discovery of a new cancer treatment.

#NobelPrize

[MoTarek @MoTarekM]

@madfunctions Congrats Ehsan, Nice piece of work. I hope it can accelerate symbolic regression approaches.

[MoTarek @MoTarekM]

@DrStass @gowerfulScience @s_jahangiri Congrats, very nice work. May you please share the scoring system that might help us identify Ven responsive subset of patients?

[MoTarek @MoTarekM]

@NicoGagelmann It seems to be global. I imagined it was a local issue.

[MoTarek @MoTarekM]

@madfunctions Could it be the graph representation of the statue material/colours leading to historical analysis of connections in his era? Or the design concept be explained by nodal representation of the face parts?

[MoTarek @MoTarekM]

@madfunctions You will, You ve set your standards already high.

[Jason Sheltzer @JSheltzer]

Another scientist whose work initially didn't get the recognition that it deserved - Victor Ambros was denied tenure at Harvard, even after publishing the seminal work that resulted in him receiving the Nobel Prize today!

[MoTarek @MoTarekM]

@madfunctions Are you working on GP for optimization?

[MoTarek @MoTarekM]

@madfunctions Brilliant!

[MoTarek @MoTarekM]

@madfunctions Congrats 👏

[MoTarek @MoTarekM]

@ManniMD1 We had very challenging experience with teclistamab, 100% of the cohort got very challenging pneumonia, fatal in 50% of the patients, difficult to manage with the rest of patients. It seems that current prophylaxis may not be enough. Usually severe GGOs, crazy paving on CT.

[David R. Liu @davidrliu]

The first prime editing clinical trial has been cleared by @US_FDA to begin: prime editing of HSCs to treat chronic granulomatous disease (CGD). Congratulations to @PrimeMedicine on achieving this key milestone only 4.5 years after we published the first prime editing paper.

[David Steensma, MD @DavidSteensma]

Not often that we see cyclophosphamide and haploidentical hematopoietic cell transplantation as the focus of a feature article in a mainstream magazine. Nice write-up in @TheAtlantic: @CIBMTR @ASH_hematology https://t.co/9tkMW0dZNQ

[Anand Patel @Anand_88_Patel]

A very nice paper in @BloodJournal elucidating the mechanisms of resistance to inotuzumab in B-ALL that go beyond loss of CD22

https://t.co/DJ7fZ4nnSN

[Niko McCarty. @NikoMcCarty]

Shanghai Jiao Tong University has an entire five-story building solely for teaching labs.

Undergraduate students can take hands-on courses in protein design, fermentation, gene-editing, and much more.

I haven't seen programs of a comparable scale for undergrads in the U.S.

[Quanta Magazine @QuantaMagazine]

Michel Talagrand has been awarded the Abel Prize, one of the highest honors in mathematics, for applying tools from high-dimensional geometry to complex probability problems. @jordanacep reports: https://t.co/JonxMN34u6

[The Nobel Prize @NobelPrize]

BREAKING NEWS
The 2023 #NobelPrize in Physiology or Medicine has been awarded to Katalin Karikó and Drew Weissman for their discoveries concerning nucleoside base modifications that enabled the development of effective mRNA vaccines against COVID-19.

[Jason Sheltzer @JSheltzer]

In 10 days, the Nobel Prize in Medicine/Physiology will be awarded.

Here are the 73 scientists most likely to get woken up by a phone call from Stockholm, based on looking at recent pre-Nobel “predictor” prizes:

[David R. Liu @davidrliu]

Today we report in @CellCellPress a suite of engineered and PACE-evolved prime editor variants PE6a-g. These new prime editors improve the activity, in vivo deliverability, and in vivo editing efficiency of prime editing.
https://t.co/xdF6j0zn8Y
PDF:https://t.co/iRegR74CKg
(1/15)

[Gene Investing w/Anthony 🧬 @GeneInvesting]

My attempt at a COMPLETE LIST of all of the diseases/programs and cancer treatments that are in development by #CRISPR #GeneEditing companies

All in IND-enabling studies or clinic...

1. Sickle Cell Disease (CRSP, EDIT, BEAM)
2. Beta Thalassemia (CRSP, EDIT, BEAM)
3. ATTR- Amyloidosis (NTLA)
4. Hereditary Angioedema (NTLA)
5. CD19+ malignancies (CRSP)
6. Autologous, CD123 / AML (Avencell)
7. Autologous, PSMA / solid tumors (Avencell)
8. CD123/ AML allogeneic (Avencell)
9. HIV (Excision)
10. CD70 solid tumors/hematologic malignancies (CRSP)
11. Allogeneic nti-CD19 CAR-T relapsed/refractory B cell non-Hodgkin lymphoma (r/r B-NHL) (CRBU)
12. T-cell ALL CD7+ AML (BEAM)
13. Allogeneic anti-BCMA CAR-T relapsed/refractory multiple myeloma (r/r MM) (CRBU)
14. Alpha-1 Antitrypsin Deficiency (NTLA, BEAM)
15. Glycogen Storage Disease 1a (BEAM)
16. Allogeneic anti-CLL-1 CAR-T relapsed/refractory acute myeloid leukemia (r/r AML) (CRBU)
17. CD30+ Lymphomas (NTLA)
18. Anti-CD83 autologous CAR-T (CRSP)
19. Type 1 Diabetes (CRSP)
20. Heterozygous familial hypercholesterolemia (VERV w/ BEAM)
21. ANGPTL3 (CRSP)
22.Homozygous familial hypercholesterolemia (VERV w/ BEAM)
23. Hemophilia B (NTLA)
24. Chronic Granulomatous Disease (PRME)
25. Autologous aß T Cells-10 programs (EDIT w/ Brystol Myers)

SOME OTHERS NOT to IND enabling yet...

ASCVD with High Lp(a) (VERV)
Stargardt Disease (BEAM)
Wilson's Disease (PRME)
Retinitis Pigmentosa/Rhodopsin (PRME)
Friedreich’s Ataxia (PRME)
Hemophilia A (NTLA)
Hepatitis B (BEAM)

Left off most of the really early programs for now.

If you are a member of the #CrisprCrew make sure you bookmark this- as it is a nice collection to look back at.

$CRSP $NTLA $BEAM $PRME $CRBU $VERV $EDIT

As always, please let me know if I forgot any!

[Niko McCarty. @NikoMcCarty]

We can design proteins on a computer that have wonderful new functions. But it's too expensive to make and test them in the real world.

My latest blog is about a protein printer that turns digital bits into physical molecules, using flashes of light.

https://t.co/ZaEvwDoC3Y
***

This essay is a thought experiment; it's speculative. But we hope it spurs conversation about how we might accelerate protein design.

I hope you'll give it a read and send me your thoughts. This article was co-written by @julian_englert.

Thanks to everyone who gave comments and feedback, including @erika_alden_d and @yestello.